INSM
NASDAQ · Biotechnology
Insmed Inc
$114.41
+5.65 (+5.19%)
Financial Highlights (FY 2026)
Revenue
635.49M
Net Income
-1,337,988,428
Gross Margin
79.7%
Profit Margin
-210.5%
Rev Growth
+35.2%
D/E Ratio
0.99
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 79.7% | 79.7% | 43.9% | 43.9% |
| Operating Margin | -205.6% | -185.0% | 2.8% | 3.5% |
| Profit Margin | -210.5% | -200.0% | 2.4% | 3.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 635.49M | 470.04M | 44.36B | 43.93B |
| Gross Profit | 506.68M | 374.76M | 19.46B | 19.27B |
| Operating Income | -1,306,503,391 | -869,713,795 | 1.25B | 1.55B |
| Net Income | -1,337,988,428 | -890,672,770 | 1.08B | 1.36B |
| Gross Margin | 79.7% | 79.7% | 43.9% | 43.9% |
| Operating Margin | -205.6% | -185.0% | 2.8% | 3.5% |
| Profit Margin | -210.5% | -200.0% | 2.4% | 3.1% |
| Rev Growth | +35.2% | +35.2% | +19.4% | +5.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 5.92B | 5.92B | 8.61B | 10.21B |
| Total Equity | 6.01B | 6.01B | 24.15B | 26.36B |
| D/E Ratio | 0.99 | 0.99 | 0.36 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -1,300,260,720 | -913,644,736 | 2.00B | 1.93B |
| Free Cash Flow | — | — | 843.11M | 852.61M |